John Byrd

Academic history

John Byrd currently serves as the Chair of the Department of Internal Medicine at the University of Cincinnati and holds the Gordon and Helen Hughes Taylor Chair. Prior to this, Prof. Byrd served as Distinguished University Professor at The Ohio State University, Columbus, OH, Co-Leader of the Leukemia Research Program, and Senior Advisor of Experimental Therapeutics at the The James Cancer Hospital and Solove Research Institute in Columbus, OH. Prof. Byrd is also a principal and Chief Medical Officer for Beat AML, a division of the Leukemia and Lymphoma Society.

Prof. Byrd received his medical degree from the University of Arkansas College of Medicine, Little Rock, AR, and subsequently completed his residency and a fellowship in medical oncology at the Walter Reed Army Medical Center, Washington, DC, as well as a further fellowship in medical oncology at the Johns Hopkins Medical Center, Baltimore, MD. He is also a member of the National Cancer Institute’s Leukemia Steering Committee and the American Society of Clinical Investigation, and Chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.

Speaking on lymphoma, leukemia, neoplasms

Prof. Byrd’s research primarily involves treating patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), with a particular focus on translational immune and molecular pharmacology. Prof. Byrd has over 600 publications in the area of leukemia and experimental therapeutics research, and his effort has resulted in numerous CLL drugs (rituximab, idelalisib, ibrutinib and acalabrutinib) receiving FDA approval.